Obiettivo SET solution for chronic pain. 100 million EU sufferers, €300 billion, Age related. Current solutions do not look at data, biomarkers, or take into consideration the individual differences between patients. With real data from large groups of patients, for the first time we can characterize the autonomic nervous system, which is depreciated in chronic pain patients, and use it to fight chronic pain. With the therapy, we attack the underlying psychological cause for the pain. The SET device allows us to do this efficiently. Using ICT data, we will be able to a real progress on this large social problem. By iterating, continuing to add data, measuring results, and adjusting approaches, we can attack chronic pain and make people pain free.SET was tested at the University of Marburg with 120 patients that included 2 sham protocols. Of the non-control participants, 100% of fibromyalgia patients became pain free for six months, and 82% at the 12-month follow-up.The data, which includes all the EKG and blood pressure data from each patient session as well as the patients' initial interview and progress data from the E-learning system, will be uploaded to a MySQL database hosted on a medical grade cloud server. Data mining and analytics software will only have read access and only anonymized access will be available, so that it will not be possible to identify any individual patient.Patent protection, a highly experienced team, a clear strongly motivated market will make the company successful. In the process many therapy based SMEs will be formed and enhanced.A real solution for a debilitating social problem which invloves ICT, big data, and job creation. Campo scientifico medical and health sciencesclinical medicinepsychiatrysleep disordersmedical and health sciencesclinical medicineintegrative and complementary medicinemedical and health sciencesclinical medicinerheumatologymedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicineoncologybreast cancer Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Argomento(i) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2016-2017 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore KLEINKLEIN GMBH Contribution nette de l'UE € 50 000,00 Indirizzo LEHMGRUBENWEG 17 88131 Lindau Germania Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Bayern Schwaben Lindau (Bodensee) Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00
